2. Committee for Proprietary Medicinal Products (CPMP). CPMP position statement on new variant CJD and plasma-derived medicinal
products. London (UK): European Agency for the Evaluation of Medicinal Products; 1998 Feb 25.
3. Zoon K. To manufacturers of biological products. Letter. Rockville (MD): Dept. of Health and Human Services (US), Center
for Biologics Evaluation and Research; 2003 Apr 19.
4. European Medicines Agency (EMEA). Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy
agents via human and veterinary medicinal products (EMEA/410/01). Revised. London (UK): EMEA; 2003 Oct 2.
5. Jayme DW, Blackman KE. Culture media for propagation of mammalian cells, viruses, and other biologicals. Adv Biotech Processes
1985;5:1-30.
6. Kan M, Yamane I. In vitro proliferation and lifespan of human diploid fibroblast in serum free BSA containing medium.
J Cell Phys 1982;111:155-62.
7. Froud SJ. The development, benefits and disadvantages of serum-free media [review]. Dev Biol Stand 1999;99:157-66.
8. Morris AE, Schmid J. Effects of insulin and LONG® R3 on serum-free Chinese hamster ovary cell cultures expressing two
recombinant proteins. Biotechnol Prog 2000 Sep-Oct;16(5):693-7.
9. Sunstrom NA, Gay RD, Wong DC, Kitchen NA, DeBoer L, Gray PP. Insulin-like growth factor-I and transferrin mediate growth
and survival of Chinese hamster ovary cells. Biotechnol Prog 2000 Sep-Oct;16(5):698-702.
10. Iglesias J, Abernethy VE, Wang Z, Lieberthal W, Koh JS, Levine JS. Albumin is a major serum survival factor for renal
tubular cells and macrophages through scavenging of ROS. Am J Physiol Renal Physiol 1999;277: F711-22.
11. Yandell CA, Lawson J, Butler I, Wade B, Sheehan A, Grosvenor S, et al. An analog of IGF-I, a potent substitute for insulin
in serum-free manufacture of biologics by CHO cells. Bioprocess Int 2004 Mar;2(3):6-64.
12. Voorhamme D, Yandell CA. LONGĖR_IGF-I as a more potent alternative to insulin in serum-free culture of HEK293 cells. Molecular
Biotech 2006;34:201-4.
13. Sargent PJ, Farnaud S, Cammack R, Zoller HMP, Evans RW. BioMetals 2006 Oct;19(5):513-9.
14. Emerson TE Jr. Unique features of albumin: a brief review. Crit Care Med 1989; Jul;17(7):690-4.
15. Tarelli E, Mire-Sluis A, Tivnann HA, Bolgiano B, Crane DT, Gee C, et al. Recombinant human albumin as a stabilizer for
biological materials and for the preparation of international reference reagents. Biologicals 1998 Dec;26(4):331-46.
16. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis and assembly of hepatitis B virus surface antigen particles
in yeast. Nature 1982;298:347-50.
17. Hollenberg CP, Gellissen G. Production of recombinant proteins by methylotrophic yeasts. Current Opinion in Biotech 1997
Oct;8(5):554-60.
18. Cereghino GPL, Cregg JM. Applications of yeast in biotechnology: protein production and genetic analysis. Current Opinion
in Biotech 1999 Oct;10 (5):422-7.
19. Sleep D, Belfield GP, Balance DJ, Steven J, Jones S, Evans LR, et al. Saccharomyces cerevisiae strains that overexpress
heterologous proteins. Biotech 1991;9:183-7.
20. Sleep D, Finnis C, Evans, L. Enhanced protein expression through strain selection, gene disruption, improved vector design
and co-expression of endogenous chaperones. Microbial Cell Fact 2006;5(Suppl 1):S29.
|
